REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in a Phase 1b clinical trial of anti-DLL4/VEGF bispecific antibody (OMP-305B83) plus chemotherapy in patients with second-line metastatic colorectal cancer.
The anti-DLL4/VEGF is the first antibody developed utilizing OncoMed's BiMAb™ bispecific platform technology and is designed to have anti-cancer stem cell, immunomodulatory and anti-angiogenic activity. Thirty patients with metastatic colorectal cancer who have failed first-line treatment, typically bevicizumab plus FOLFOX (folinic acid, fluorouracil, oxaliplatin) chemotherapy, will receive second-line treatment in the Phase 1b multicenter, open-label dose escalation and expansion study of the anti-DLL4/VEGF bispecific antibody in combination with FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy. This trial is designed to determine the safety, preliminary efficacy, immunogenicity, pharmacokinetics and biomarker effects of the anti-DLL4/VEGF bispecific antibody plus FOLFIRI. A second Phase 1b study in patients with platinum resistant ovarian cancer is expected to begin enrolling patients soon.
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=1006300
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population
Silk Road Medical Announces Updated Clinical Data on TCAR Presented at the 44th Annual VEITH Symposium
Via: Yahoo! Finance
SUNNYVALE, Calif., Dec. 12, 2016 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced that the 44th annual VEITH Symposium held November 15-19, 2016, in New York City featured several presentations on the company's ENROUTE® Transcarotid Neuroprotection and Stent System, the first and only products specifically designed and indicated for TransCarotid Artery Revascularization (TCAR). Highlights include 1-year data on the pivotal cohort from ROADSTER 1 and the first interim analysis of the 30-day data from the ROADSTER 2 Post Approval Study.
Via: Business Wire
Former Head of Novartis’ Pharmaceuticals Division to help guide future of company focused on groundbreaking therapy for CNS-related edema
OncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Partial Responses and Stable Disease Achieved with Bispecific as a Single-Agent
REDWOOD CITY, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented initial first-in-human data from its ongoing Phase 1 clinical trials of anti-DLL4/VEGF bispecific (OMP-305B83) and anti-RSPO3 (OMP-131R10) antibodies in two posters at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium being held in Munich, Germany.
Via: The Mercury News
To most, it’s Silicon Valley: the region that produced silicon chip innovators and manufacturers, globally influential high-tech corporations and thousands upon thousands of startup companies.
Via: Oliver Wyman Health
Here, Sean Duffy speaks with Kate Warnock of GuideWell during the Oliver Wyman Health Innovation Summit 2016 and shares how Omada Health's digital innovation and value-based model is impacting people with chronic disease.
Via: PR Newswire
Innovative Minimally Invasive Approach for Neurological Conditions Has Been Used in 1,000 Patient Procedures
Study shows seniors at risk for diabetes and heart disease lose weight, reduce healthcare costs with Omada's program
The digital behavioral health coaching program from Omada Health has been shown to reduce overweight and obese seniors' risk of developing type 2 diabetes and heart disease by helping them lose weight and adopt healthier behaviors, according to a new study.
Peer-Reviewed Study Demonstrates Omada Program Helps Seniors Reduce Risk of Type 2 Diabetes and Heart Disease
Via: Omada Health
Company’s fifth peer-reviewed publication shows seniors engage with the Omada Program and lose weight; model estimates savings in less than two years